Yale School of Medicine | Strategic Alliance Partners

“What we really want to do is have more enhanced engagement of broader populations,” says Veda Giri, MD.

"We also saw in the high-risk group that patients who identified as Black were much more likely to not receive treatment than their White counterparts," says Madison Novosel, BA.

"Given the fact that this field has really expanded, we see that patients are engaging with genetic testing in various different ways," says Veda Giri, MD.

"The Medicaid and uninsured patients had significantly lower odds of getting treatment than those who [have] private insurance," says Madison Novosel, BA.

“The field of germline testing for prostate cancer has expanded significantly; it's really become central in terms of thinking about treatment for men with metastatic prostate cancer,” says Veda Giri, MD.

Yale School of Medicine Associate Professor of Urology Michael Leapman, MD, MHS, and coauthors estimated the environmental impacts of prostate MRI and prostate biopsy.

“We need to leverage these great platforms to put out high-quality information with experts that people can listen to from home or on the go and get the information that they need,” says Stacy Loeb, MD, MSc.

"[This is] a group of patients that there are few treatments available for, and we're excited about the data," says Daniel P. Petrylak, MD.

“These data support further evaluation of sacituzumab govitecan—alone or in combination—in patients with metastatic urothelial carcinoma who progressed after prior CPI therapy,” says Daniel P. Petrylak, MD.

“It seems like podcasts really are a good way for people to learn about even a complex topic like this,” says Stacy Loeb, MD, MSc.

“I think this is a nice cluster of podcasts that really go at this from different angles,” says Stacy Loeb, MD, MSc.

“So many patients with prostate cancer qualify for genetic testing, but it's currently underutilized,” says Stacy Loeb, MD, MSc.

An associate professor of Urology at Yale School of Medicine, Dr. Kenney specializes in treating genitourinary cancers, with a particular focus on kidney cancers.

"I think there's a lot of fear that can go into talking about these topics," says Katherine Rotker, MD.

“We now have convincing evidence that these tests help identify more sites of prostate cancer," said Michael Leapman, MD.

"We increasingly see the evolving role of ‘precision medicine’ in urology, using genetic and genomic testing to guide [management] for a variety of diseases, particularly bladder and prostate cancer," says 1 urologist.

A Yale chemist and oncologist collaborated to create a new treatment for prostate cancer that tags specific proteins within the cancerous cells, making it easier for the body’s natural mechanisms to identify and destroy them.

"I have no doubt we’ll become a destination program. We have a great team. Combined with a few key recruitments, we will be set to take our place on the global stage of urology," says Isaac Y. Kim, MD, PhD, MBA, urology professor and chair, Yale Urology.

"It’s the most satisfying of all the things I do as a surgeon. The benefits are so dramatic and often immediate," said Daniel Kellner, MD.

Yale Urology has ranked among the top 50 urology programs in the nation and #1 in Connecticut in U.S. News & World Report’s just-released listing.

“We found that Medicaid acceptance differed widely across cancer care facilities," said Michael Leapman, MD, MHS, associate professor of Urology, clinical program leader for the Prostate & Urologic Cancers Program at Yale Cancer Center and Smilow Cancer Hospital.

Smilow Cancer Hospital offers the latest treatments for prostate cancer, including single-port robotic radical prostatectomy.

Proteolysis-targeting chimaera, or PROTACs, work by using elements of the body’s natural protein recycling system and recruiting them toward cancerous proteins

"Because testicular cancer is most often diagnosed in young men and treatments are very successful, the focus is on minimizing the short- and long-term impacts of treatment," says Sprenkle.

Preventable factors account for a large part of the formation of tumors of the bladder and skin.

In discussing treatment determinations, Petrylak noted that for patients with low PD-L1 expression had decreased survival benefits compared with patients treated with chemotherapy in the monotherapy arms of the phase 3 KEYNOTE-361 (NCT02853305) and phase 3 IMVIGOR-130 (NCT02807636) trials.

“There are many trials that clinicians should be aware of,” says Daniel P. Petrylak, MD.

“One of the reasons I so enjoy this conference is the multidisciplinary nature,” says Peter A. Humphrey, MD, PhD.

“This first disclosure of data supports the ongoing phase 2 and 3 programs evaluating enfor-tumab vedotin alone or in combination with pembrolizumab in MIBC,” said Daniel P. Petrylak, MD.

"These findings underscore the importance of screening guidelines from the task force and the rapid responsiveness of clinicians and patients,” said Michael S. Leapman, MD.